---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-007825"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T14:10:55.963473+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Pure Bioscience shareholders approve increase in authorized shares to 200M

## Summary
- All six director nominees elected with 97-99% of votes cast; terms until next annual meeting.
- Ratification of Weinberg & Company as auditor for FY ending July 31, 2024 approved (99.58%).
- Non-binding advisory vote on executive compensation passed with 99.14% of votes cast.
- 2024 Equity Incentive Plan adopted with 99.17% of votes cast.
- Amendment to increase authorized common stock from 150M to 200M shares approved with 55.13% of outstanding shares.

## SEC filing metadata
- accession: 0001493152-24-007825
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-007825
- JSON: https://secwatch.observer/filing/0001493152-24-007825.json
- Plain text: https://secwatch.observer/filing/0001493152-24-007825.txt

## Key facts
- Shareholder Votes
  PURE BIOSCIENCE, INC. shareholders approved Election of Directors at the 2024-02-21 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-02-21
  source text: Director For Withheld Broker Non-Votes Tom Y. Lee, CPA 51,623,453 386,540 12,237,539 Ivan Chen 51,598,411 411,582 12,237,539 Tom Myers 51,643,956 366,037 12,237,539 David M. Rendall 51,637,237 372,756 12,237,539 Robert Bartlett 51,667,737 342,256 12,237,539 Bernard Blotner 50,457,923 1,552,070 12,237,539
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm
- Shareholder Votes
  PURE BIOSCIENCE, INC. shareholders approved Ratification of Auditors at the 2024-02-21 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-02-21
  source text: For Against Abstentions 63,801,664 268,958 176,910
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm
- Shareholder Votes
  PURE BIOSCIENCE, INC. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 150,000,000 to 200,000,000 at the 2024-02-21 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2024-02-21
  source text: For Against Abstentions 61,666,543 2,226,172 314,817
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm
- Shareholder Votes
  PURE BIOSCIENCE, INC. shareholders approved Adoption of the 2024 Equity Incentive Plan at the 2024-02-21 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2024-02-21
  source text: For Against Abstentions Broker Non-Votes 48,041,487 401,589 3,566,917 12,237,539
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm
- Shareholder Votes
  PURE BIOSCIENCE, INC. shareholders approved Executive Compensation (non-binding advisory vote) at the 2024-02-21 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-02-21
  source text: For Against Abstentions Broker Non-Votes 48,049,734 412,190 3,548,069 12,237,539
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.